Vincent Aurentz - 21 Feb 2026 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Mark Iwicki, attorney-in-fact
Issuer symbol
IKT
Transactions as of
21 Feb 2026
Net transactions value
$0
Form type
4
Filing time
24 Feb 2026, 20:54:26 UTC
Previous filing
02 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aurentz Vincent Director 1000 N. WEST STREET, SUITE 1200, WILMINGTON /s/ Mark Iwicki, attorney-in-fact 24 Feb 2026 0001657494

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IKT Common Stock Disposed to Issuer $0 -255,299 -33% $0.000000 510,596 21 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 255,299 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 255,299 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.